Lifestyle Natural Medicines
Monte Rosa Therapeutics (NASDAQ:GLUE) Rating Reiterated by Piper Sandler
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Piper Sandler in a report released on Friday, Benzinga reports. They currently have a $16.00 price target on th
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Piper Sandler in a report released on Friday, Benzinga reports.… [+3422 chars]
Related
Share this page
Guest Posts by Easy BranchesGet Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.